Showing results (351-360 of 760) with videos related to

Sort By:
Pageof 76
Leukemia|January 27, 2022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Cancer|October 17, 2023
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myelomaWenqiang Yan, Jingyu Xu, Huishou Fan, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
British Journal of Haematology|April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myelomaYutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Blood|January 30, 2010
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Monette Aujay, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 7, 2024
Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studiesDanka Cholujova, Zdenka Lukacova Bujnakova, Erika Dutkova, et al.
Pageof 76